Cost and cost-effectiveness of tongue swab-based molecular testing for tuberculosis in the Philippines, Uganda, Vietnam, and Zambia
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Tongue swabs (TS) offer a promising alternative to sputum-based molecular testing for tuberculosis. However, the health and cost implications of TS-based testing remain poorly understood. As part of the Tongue Swab Yield (TSwaY) study, we aimed to assess the cost and cost-effectiveness of integrating TS-based testing using MiniDock MTB Test (Guangzhou Pluslife Biotech, China), a novel rapid molecular assay, into primary healthcare in four high-burden countries.
Methods
We collected cost data from primary healthcare facilities in the Philippines, Uganda, Vietnam, and Zambia. We estimated incremental cost-effectiveness ratios (ICERs) for (1) TS MiniDock MTB Test as a replacement for sputum Xpert Ultra, and (2) combined testing in which TS MiniDock MTB Test is used for sputum-scarce people and those with negative/indeterminate sputum results. ICERs were estimated with respect to the current sputum Xpert Ultra strategy. Net monetary benefits (NMB) were estimated across willingness-to-pay (WTP) thresholds. Best estimates were based on observed diagnostic yield, with 95% uncertainty intervals (95%UI) derived from probabilistic simulation.
Findings
Among 1,370 participants, sputum Xpert Ultra resulted in 67 (95%UI: 46–89) bacteriologically confirmed tuberculosis diagnoses at an estimated cost of USD 507 per diagnosis. Replacing sputum Xpert Ultra with TS MiniDock MTB Test reduced total costs but yielded fewer diagnoses (62 [95%UI: 42–83]). The combined testing strategy led to 22 (95%UI: 13–30) additional diagnoses at an incremental cost of USD 742 (95%UI: 514–1,267) per additional diagnosis and yielded the highest NMB at WTP thresholds above USD 1,077. Limiting TS MiniDock MTB Test to sputum-scarce individuals yielded 7 (95%UI: 2–13) additional diagnoses at an incremental cost of USD 196 (95%UI: 106–695) per additional diagnosis.
Interpretation
Combining sputum- and TS-based molecular testing can improve tuberculosis detection at reasonable additional cost. Our findings support integrating TS MiniDock MTB Test into diagnostic algorithms in high-burden settings.
Funding
Gates Foundation.
